FDA Accepts New Drug Application for Mezigdomide in Combination with Carfilzomib and Dexamethasone as Treatment for Relapsed/Refractory Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/fda-accepts-new-drug-application-mezigdomide-rrmm)